Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lineage Cell Therapeutics (LCTX) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to -$3.4 million.

  • Lineage Cell Therapeutics' Net Income towards Common Stockholders fell 1396.2% to -$3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$32.0 million, marking a year-over-year decrease of 5974.76%. This contributed to the annual value of -$18.6 million for FY2024, which is 1348.76% up from last year.
  • Latest data reveals that Lineage Cell Therapeutics reported Net Income towards Common Stockholders of -$3.4 million as of Q3 2025, which was down 1396.2% from -$19.3 million recorded in Q2 2025.
  • Lineage Cell Therapeutics' Net Income towards Common Stockholders' 5-year high stood at -$1.4 million during Q1 2021, with a 5-year trough of -$28.0 million in Q4 2021.
  • Moreover, its 5-year median value for Net Income towards Common Stockholders was -$6.0 million (2025), whereas its average is -$7.2 million.
  • Within the past 5 years, the most significant YoY rise in Lineage Cell Therapeutics' Net Income towards Common Stockholders was 8281.92% (2021), while the steepest drop was 294644.31% (2021).
  • Quarter analysis of 5 years shows Lineage Cell Therapeutics' Net Income towards Common Stockholders stood at -$28.0 million in 2021, then skyrocketed by 77.29% to -$6.4 million in 2022, then increased by 25.9% to -$4.7 million in 2023, then surged by 31.06% to -$3.2 million in 2024, then fell by 5.23% to -$3.4 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$3.4 million for Q3 2025, versus -$19.3 million for Q2 2025 and -$6.0 million for Q1 2025.